Long lasting complete molecular remission after suspending dasatinib treatment in chronic myeloid leukemia

Tyrosine kinase inhibitors specific for BCR-ABL, were a major breakthrough in CML therapy. Second generation tyrosine kinase inhibitors (dasatinib, nilotinib) are indicated for imatinib resistant and intolerant patients. Present guidelines recommend continuous drug dosing for maintaining remission....

Descripción completa

Detalles Bibliográficos
Autores principales: Gadó, Klára, Matolcsy, András, Csomor, Judit, Kicsi, Dóra, Bödör, Csaba, Domján, Gyula
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3514089/
https://www.ncbi.nlm.nih.gov/pubmed/23210842
http://dx.doi.org/10.1186/2162-3619-1-17

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3514089/
https://www.ncbi.nlm.nih.gov/pubmed/23210842
http://dx.doi.org/10.1186/2162-3619-1-17

Ejemplares similares